[Heparin-induced thrombocytopenia: a brief update in an Italian perspective].
Type-2 heparin-induced thrombocytopenia (HIT) is a not infrequent complication of treatment with heparins which can lead to fatal outcomes if not recognized and timely treated. Over the last years new epidemiological knowledge, new diagnostic approaches and new therapeutic options have become available. In the present review such novelties will be briefly discussed in the frame of Italian Health System. In Italy only one drug is approved for use in HIT patients differently from other countries. Alternative possible therapeutic options will be discussed based on the scarce available evidence.
Prisco
Domenico
D
D000077425:Fondaparinux; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology; D006629:Hirudins; D006801:Humans; D007558:Italy / Q000453:epidemiology; D015539:Platelet Activation / Q000187:drug effects; D010978:Platelet Factor 4 / Q000276:immunology; D011134:Polysaccharides / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control
D006629:Hirudins; D011134:Polysaccharides; D011994:Recombinant Proteins; D010978:Platelet Factor 4; D006493:Heparin; D000077425:Fondaparinux; C083544:lepirudin